3SBio reports higher revenue. 3SBio stock loses 1.12 percent.

Published on 10/05/2026 at 14:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 3.90 percent to RMB 4.53 billion. 3SBio stock costs EUR 1.77 on October 5, 2026 after EUR 1.79, down 1.12 percent.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

3SBio (ISIN KYG8875G1029) was trading at EUR 1.77 at Lang & Schwarz on October 5, 2026 at 2:08 p.m. CEST, down 1.12 percent from the prior close of EUR 1.79. The six-month results published on September 30 showed revenue rising 3.90 percent year on year to RMB 4.53 billion, according to Moomoo.

Revenue rose 3.90 percent

The headline growth came with a sharper change in the revenue mix. Outbound licensing income contributed RMB 850 million, while CDMO revenue increased 160.90 percent year on year to RMB 230 million, according to Moomoo.

Biologics sales moved in the opposite direction, falling 19.30 percent to RMB 3.44 billion in the first half of 2026. The contrast matters because the licensing and CDMO contributions helped offset pressure on the established product portfolio.

Profit mix tells the bigger story

Net profit attributable to equity shareholders declined 15.60 percent year on year to RMB 1.15 billion in the first half of 2026, while adjusted operating net profit rose 26.50 percent to RMB 1.44 billion. Basic earnings per share were RMB 0.45, and the board did not recommend an interim dividend, Moomoo reported.

Research spending increased 24.90 percent to RMB 680 million, equal to 15.10 percent of revenue. That investment supports late-stage programs in oncology, autoimmune disease, nephrology, metabolism and dermatology, but reimbursement reforms and centralized procurement remain stated risks for traditional products.

Analyst target remains above HKD 30

Shenwan Hongyuan maintained a Buy rating and set a HKD 30.40 price target, according to The Globe and Mail on September 20, 2026. The same report placed the analyst consensus target at HKD 29.34, while 3SBio shares had closed at HKD 15.75 in the cited comparison.

A separate analysis from Futu on September 22, 2026 kept an Add rating and highlighted the pipeline, including multiple Phase III studies for PF-08634404/707. Its analysis also cited RMB 231 million of first-half CDMO revenue, up 160.87 percent year on year.

Stock trades below prior close

At Lang & Schwarz, 3SBio was trading at EUR 1.77 on October 5, 2026 at 2:08 p.m. CEST, versus a prior close of EUR 1.79 on October 2, 2026. On the Hong Kong Stock Exchange, the stock was quoted at HKD 15.54 on October 5, 2026, within a 52-week range of HKD 14.81 to HKD 35.42.